<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02458976</url>
  </required_header>
  <id_info>
    <org_study_id>2015P000196</org_study_id>
    <nct_id>NCT02458976</nct_id>
  </id_info>
  <brief_title>Pulsed-dye Laser Treatment Prior to Surgical Excision</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective pilot study will investigate whether use of a pulsed dye laser (PDL) prior&#xD;
      to surgical excision can improve the appearance and symptoms of scars. The primary outcome&#xD;
      measurement for the study is the quality of the scar in areas pre-treated with PDL vs.&#xD;
      control (cryogen spray only). For this study, subjects who are scheduled for a dermatologic&#xD;
      surgical excision will have half of the surgical area pre-treated with PDL and the other half&#xD;
      pre-treated with cryogen spray.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Scar appearance</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Cicatrix</condition>
  <arm_group>
    <arm_group_label>PDL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pre-treatment of surgical area with PDL</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PDL</intervention_name>
    <arm_group_label>PDL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects with ages between 18 and 65 years, who are scheduled for a dermatologic&#xD;
             surgical excision&#xD;
&#xD;
          -  Subjects requiring surgical excisions for any condition&#xD;
&#xD;
          -  Subjects with any Fitzpatrick skin type&#xD;
&#xD;
          -  Willingness to participate in the study&#xD;
&#xD;
          -  Willingness to receive experimental treatment&#xD;
&#xD;
          -  Informed consent agreement signed by the subject&#xD;
&#xD;
          -  Willingness to follow the follow-up schedule&#xD;
&#xD;
          -  Willingness to not use any other scar treatments during the study period (i.e scar&#xD;
             massage, over-the-counter silicone pads, intralesional steroid of 5-fluorouracil&#xD;
             injections, laser treatments)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Prior scar in area to be treated&#xD;
&#xD;
          -  Known photoallergy to visible light (i.e polymorphous light eruption)&#xD;
&#xD;
          -  Subject is unable to comply with treatment or follow-up visits&#xD;
&#xD;
          -  Subject with a history of being on photosensitive medications for the past 3 months&#xD;
             (thiazides [used to treat high blood pressure], tetracyclines, fluoroquinolones&#xD;
             griseofulvin or sulfonamides [used to treat infections], sulfonylureas [used to treat&#xD;
             diabetes], calcium channel blockers [used to treat hypertension], phenothiazines [used&#xD;
             to treat serious emotional problems]).&#xD;
&#xD;
          -  Known autoimmune disease (some autoimmune diseases can lead to sensitivity to light,&#xD;
             such as lupus erythematosus)&#xD;
&#xD;
          -  Subject is currently enrolled in a clinical study of any other unapproved&#xD;
             investigational drug or device&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>R R Anderson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MGH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kachiu Lee, MD</last_name>
    <phone>617-371-4711</phone>
    <email>klee52@mgh.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Beverly Dammin</last_name>
    <phone>617-726-3308</phone>
    <email>bdammin@mgh.harvard.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kachiu Lee, MD</last_name>
      <phone>617-371-4711</phone>
      <email>klee52@mgh.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Beverly Dammin</last_name>
      <phone>617-726-3308</phone>
      <email>bdammin@mgh.harvard.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Richard R Anderson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>May 28, 2015</study_first_submitted>
  <study_first_submitted_qc>May 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 1, 2015</study_first_posted>
  <last_update_submitted>April 18, 2017</last_update_submitted>
  <last_update_submitted_qc>April 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Richard Rox Anderson, MD</investigator_full_name>
    <investigator_title>Professor of Dermatology</investigator_title>
  </responsible_party>
  <keyword>Scar</keyword>
  <keyword>Pulsed-dye laser</keyword>
  <keyword>PDL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cicatrix</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

